Arjen van der Veen

Arjen van der Veen

Auto-generated profile, based on publicly available information

Arjen van der Veen

Department of Surgery, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 March 2021 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
AVArjen van der Veen
Arjen van der Veen
HBHylke Brenkman
Hylke Brenkman
MSMaarten F. J. Seesing
Maarten F. J. Seesing
LHLeonie Haverkamp
Leonie Haverkamp
MLMisha D. P. Luyer
Misha D. P. Luyer
HLHanneke W. M. van Laarhoven
Hanneke W. M. van Laarhoven
BACKGROUND: The oncological efficacy and safety of laparoscopic gastrectomy are under debate for the Western population with predominantly advanced gastric cancer undergoing multimodality treatment. METHODS: In 10 experienced upper GI centers in the Netherlands, patients with resectable (cT1-4aN0-3bM0) gastric adenocarcinoma were randomly assigned to either laparoscopic or open gastrectomy. No masking was performed. The primary outcome was hospital stay. Analyses were performed by intention to treat. It was hypothesized that laparoscopic gastrectomy leads to shorter hospital stay, less postoperative complications, and equal oncological outcomes. RESULTS: Between 2015 and 2018, a total of 227 patients were randomly assigned to laparoscopic (n = 115) or open gastrectomy (n = 112). Preoperative chemotherapy was administered to 77 patients (67%) in the laparoscopic group and 87 patients (78%) in the open group. Median hospital stay was 7 days (interquartile range, 5-9) in both groups ( P = .34). Median blood loss was less in the laparoscopic group (150 v 300 mL, P < .001), whereas mean operating time was longer (216 v 182 minutes, P < .001). Both groups did not differ regarding postoperative complications (44% v 42%, P = .91), in-hospital mortality (4% v 7%, P = .40), 30-day readmission rate (9.6% v 9.1%, P = 1.00), R0 resection rate (95% v 95%, P = 1.00), median lymph node yield (29 v 29 nodes, P = .49), 1-year overall survival (76% v 78%, P = .74), and global health-related quality of life up to 1 year postoperatively (mean differences between + 1.5 and + 3.6 on a 1-100 scale; 95% CIs include zero). CONCLUSION: Laparoscopic gastrectomy did not lead to a shorter hospital stay in this Western multicenter randomized trial of patients with predominantly advanced gastric cancer. Postoperative complications and oncological efficacy did not differ between laparoscopic gastrectomy and open gastrectomy.

1 September 2018 in Diseases of the Esophagus
Verified
Journal Article
Closed access
PDF file
AVA Van Der Veen
A Van Der Veen
MSMfj Seesing
Mfj Seesing
HBHjf Brenkman
Hjf Brenkman
HSHba Stockmann
Hba Stockmann
GNGap Nieuwenhuijzen
Gap Nieuwenhuijzen
RHRichard van Hillegersberg
Richard van Hillegersberg
Best supportive care or palliative chemotherapy is the standard of care for gastroesophageal cancer patients with hepatic or pulmonary metastases, leading to a median survival of 4–11 months. Occasionally, patients with oligometastatic disease may be eligible for curative treatment. The aim of the current study was to evaluate the outcomes of all patients in the Netherlands who underwent a resection of hepatic or pulmonary metastases with curative intent for metastatic gastroesophageal cancer. The Dutch National Registry for Histo- and Cytopathology was used to identify all patients who underwent a resection of hepatic or pulmonary metastasis from gastroesophageal cancer. Patients who were treated with curative intent and had available patient records were included. Data on treatment and outcomes were retrieved from the patient's record. Kaplan-Meier survival analysis was performed. The primary tumor of 34 patients with gastroesophageal cancer was resected in 21 different hospitals between 1991–2016. Additionally, resection of hepatic metastasis was performed in 19 patients and of pulmonary metastasis in 15 patients. Only 4 patients received neoadjuvant therapy before metastasectomy. The majority of patients had solitary, metachronous metastases. After metastasectomy, grade 3 (Clavien-Dindo) complications occurred in 7 patients and mortality in 1 patient. After resection of hepatic metastases, the median overall survival (OS) was 28 months and the 1-, 3- and 5- year OS were 84%, 41% and 31% respectively. After pulmonary metastases resection, the median OS was not reached and the 1-, 3- and 5- year OS were 67%, 53% and 53% respectively. In selected patients with gastroesophageal cancer with hepatic or pulmonary metastases, metastasectomy was performed with limited morbidity and mortality and offered a 5-year OS of 31–53%. Further prospective studies are required. All authors have declared no conflicts of interest.

1 September 2018 in Diseases of the Esophagus
Verified
Journal Article
Closed access
PDF file
AVA Van Der Veen
A Van Der Veen
MSMfj Seesing
Mfj Seesing
BWBas P L Wijnhoven
Bas P L Wijnhoven
WSWo Steur
Wo Steur
Mark I. van Berge HenegouwenMark I. van Berge Henegouwen
Mark I. van Berge Henegouwen
LBLodewijk A. A. Brosens
Lodewijk A. A. Brosens
Background: Esophageal and gastric neuroendocrine- and mixed adenoneuroendocrine carcinomas (NEC, MANEC) are very rare. Optimal treatment strategies, the role of surgery and outcomes remain unclear. The aim of this study is to provide insight in accuracy of diagnosing, current treatment and survival in patients with resectable esophageal and gastric (MA)NEC. Methods: All patients with esophageal or gastric (MA)NEC, who underwent surgical resection between 2006–2016, were identified from the Dutch national registry for histo- and cytopathology (PALGA). Patients with a neuroendocrine tumor lower than grade 3 were excluded. Data on patients, treatment and outcomes were retrieved from the patients record. Diagnosis by endoscopic biopsy was compared with diagnosis by resection specimen. Kaplan Meier survival analysis was performed. Results: A total of 49 patients were identified in 25 hospitals, including 21 patients with esophageal (MA)NEC and 26 patients with gastric (MA)NEC on resection specimen. Biopsy diagnosis of (MA)NEC was correct in 23/27 patients. However, 20/47 patients with definitive diagnosis of (MA)NEC, were misdiagnosed on biopsy. Neoadjuvant therapy was administered in 13 (62%) esophageal (MA)NECs and 12 (46%) gastric (MA)NECs. Survival curves were similar with and without neoadjuvant therapy. One (4.8%) esophageal (MA)NEC and 4 (15%) gastric (MA)NECs died within 90 days postoperatively. For esophageal (MA)NEC the median overall survival (OS) after surgery was 37 months and 1-, 3- and 5-year OS were 71%, 50% and 35%, respectively. For gastric (MA)NEC, the median OS was 23 months and 1-, 3- and 5-year OS were 62%, 50% and 39%, respectively. Conclusion: Localized esophageal and gastric (MA)NEC are often misdiagnosed on endoscopic biopsies. After resection, long-term survival was achieved in respectively 35% and 39% of patients. Disclosure: All authors have declared no conflicts of interest.